Patent intelligence · US
US 10821092
Viscous topical ocular formulations
Viscous topical ocular formulations
Patent details — US 10821092
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 3, 2020
- Expiration
- Oct 29, 2040
- Applicant
- Encompass Development, Inc.
- Claims
- 17
- CPC classes
- A61K, A61K31/245, A61K31/728, A61K38/1841
Quick answer
US 10821092 (Viscous topical ocular formulations) is held by Encompass Development, Inc.. Status: granted. Granted Nov 3, 2020. Expires Oct 29, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Encompass Development, Inc.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/245, A61K31/728, A61K38/1841, A61K47/36, A61K9/0048
More from Encompass Development, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12377112
Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
granted -
US 12312375
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
granted -
US 12286483
Method of treating cancer using CD137 antibodies and PD-1 antagonists
granted -
US 12186285
Compositions and methods of treatment for tinea pedis
granted -
US 12070594
Biomedical electrode with anti-microbial properties
granted -
US 11970538
Multispecific binding constructs against checkpoint molecules and uses thereof
granted -
US 11939346
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
granted -
US 11865179
Progesterone formulations having a desirable PK profile
granted
Frequently asked questions
What is US patent 10821092?
US 10821092 (Viscous topical ocular formulations) is held by Encompass Development, Inc.. Status: granted. Granted Nov 3, 2020. Expires Oct 29, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10821092?
Encompass Development, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 100 pharmaceutical patents for this assignee.
When does US 10821092 expire?
Our index shows an expiration date of Oct 29, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.